JPRN-jRCT2080221995CompletedPhase 2
A Randomized, Placebo-controlled, Double-blind, Parallel-group, Exploratory Study of DSP-6952 in Patients with Irritable Bowel Syndrome with Constipation (Early Phase 2 Study)
Sumitomo Dainippon Pharma Co.,Ltd.0 sites175 target enrollmentStarted: December 28, 2012Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Enrollment
- 175
Study Overview
Brief Summary
DSP-6952 improved stool frequency as measured by CSBMs, abdominal symptoms, and overall IBS-C symptoms, and was well tolerated.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- >= 20age old to <= 64age old (—)
- Sex
- All
Inclusion Criteria
- •-Patients who meet the RomeIII criteria for irritable bowel syndrome with constipation
- •-Outpatients
Exclusion Criteria
- •- Patients who have history or complication of malignancy
- •- Patients who have history of medication allergy
Investigators
Similar Trials
Completed
Phase 2
Proof-of-Principle Study of TC-6499 in the Treatment of Constipation Predominant Irritable Bowel Syndrome (IBS)Irritable Bowel SyndromeNCT01149200Targacept Inc.24
Unknown
Phase 2
The Effect of Coltect (Selenium, Curcumin and Green Tea) on Irritable Bowel SyndromeIrritable Bowel SyndromeNCT01167673NAFTALI TIMNA40
Completed
Not Applicable
FMT for Patients With IBS With Fecal and Mucosal Microbiota AssessmentFecal Microbiota TransplantationIrritable Bowel SyndromeNCT03125564Chinese University of Hong Kong56
Unknown
Not Applicable
The Effect of CanChew® Cannabidiol (CBD) Containing Chewing Gum on Irritable Bowel SyndromeIrritable Bowel SyndromeNCT03003260Wageningen University40
Completed
Not Applicable
To Study the Efficacy and Safety of L. Plantarum UALp-05TM in Diarrhea- Predominant-irritable Bowel SyndromeIrritable Bowel Syndrome With DiarrheaNCT04950296Vedic Lifesciences Pvt. Ltd.314